Intra-Cellular Therapies Inc
Save
–
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Drug Manufacturers - Specialty & Generic
Industry
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications.
Similar securities
Based on sector and market capitalization
Report issue